An interventional study of Active tDCS and Sham tDCS in Depression and Pregnancy, sponsored by Women's College Hospital. Completed at 2 sites in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-31.
Sponsored by Women's College Hospital · Not applicable, Interventional, and Treatment
The purpose of this pilot study is to examine the feasibility of conducting a multi-site double-blind randomized controlled trial whose aim will be to evaluate the effectiveness of transcranial direct current stimulation (tDCS) for treatment in pregnant women with moderate to severe major depression.
Major depression is a serious condition that affects up to 10% of pregnant women, and has serious impact on the developing fetus. However current treatments are less than ideal for women with moderate to severe depression. Psychotherapy alone is either ineffective, or takes months to improve symptoms, leaving the fetus susceptible to depression during that time. Antidepressant medication is effective, but there are high refusal rates of standard pharmacological treatment because of fears about medication exposure. The highly negative impacts of depression in pregnancy on the developing fetus and child illustrate the need for evaluation of timely and innovative treatments.
Transcranial direct current stimulation (tDCS) is a non-drug treatment for depression where the dorsolateral prefrontal cortex, a part of the brain that functions abnormally when an individual is depressed, can be directly stimulated without impacting any other parts of the body or brain. As such, it is an ideal treatment for pregnant women who do not want to expose their fetus to the impact of medication treatment for depression. It has been shown to be effective in depression among non-pregnant adults and improvement is seen rapidly with a 3-week treatment course, almost 3 times faster than standard psychological treatment. There are no known serious adverse effects and no theoretical risk to a fetus.
This research study will measure the feasibility, acceptability and compliance of the tDCS as a treatment option for depression in pregnancy. In addition, the study will investigate the effect of tDCS on reducing depressive symptoms immediately post-treatment among women who have moderate to severe depression in pregnancy.
In this multi-centre, pilot randomized controlled trial, adult women with moderate to severe depression in pregnancy will be recruited from one hospital obstetrical group and two specialty perinatal mental health clinics over the course of 1 year. Women will have been offered to start or continue SSRI (Selective Serotonin Reuptake Inhibitors) or SNRI (Selective Serotonin-Norepinephrine Reuptake Inhibitors)medication but declined use. All participants will continue to receive clinical care from their respective clinical programs during the trial. Although this care may include psychotherapeutic intervention that is initiated prior to completion of the active tDCS treatment phase (if clinic psychotherapy waitlist is short), we would not expect to see improvement within the first 3 weeks of psychotherapeutic treatment. As such, this is an ideal opportunity to evaluate the efficacy of a new treatment, without depriving women of non-pharmacological standard care.
Following informed consent procedures, participants will be randomized to tDCS or a sham-control condition (1:1) with on-site treatments 5 days per week over 3 weeks in 30 minute sessions. The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered by a specially developed, battery driven constant current stimulator. The electrodes will be placed over F3 and F4 according to the international system for EEG (Electroencephalogram) placement. Sham stimulation will be administered using the same stimulation parameters and at the site of active treatment, but the current will be turned off after 30 seconds.
Women will be interviewed at baseline and then followed during treatment, every four weeks until delivery, and at four and twelve weeks postpartum to allow for measurement of depressive symptoms, pregnancy, delivery, neonatal and infant outcomes. Although baseline and treatment interviews will be conducted in person, post-treatment and post-delivery interviews will be offered in person or over the telephone, according to participant preference.
8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's enrollment of 20 is below the median of 84 across 6,720 interventional studies indexed under Depression.
Browse Depression studies →Women's College Hospital is the lead sponsor of 83 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
Device: Active tDCS
The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
Device: Sham tDCS
The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
Number of participants recruited over 1 year
Feasibility
Time frame: Up to one year from when the study starts enrolling participants
Montgomery Asberg Depression Rating Scale
Efficacy - Depression Symptom Measurement
Time frame: End of week 1
Edinburgh Postnatal Depression Scale
Efficacy - Depression Symptom Measurement
Time frame: End of Week 1
Pregnancy Experience Scale
Efficacy - Secondary Symptom Measurement
Time frame: End of Week 1
State-Trait Anxiety Inventory
Efficacy - Secondary Symptom Measurement
Time frame: End of week 1
Itemized neonatal health outcomes questionnaire
Neonatal outcome (safety)
Time frame: 4 weeks postpartum
Itemized neonatal health outcomes questionnaire
Neonatal Outcome (safety)
Time frame: 12 weeks postpartum
Bates Infant Characteristics Questionnaire
Infant outcome (temperament)
Time frame: 12 weeks postpartum
Ages and Stages Questionnaire
Infant outcome (development)
Time frame: 12 weeks postpartum
Toronto Side Effects Scale
Acceptability - side effects
Time frame: End of Week 1
Toronto Side Effects Scale
Acceptability - side effects
Time frame: End of week 2
Toronto Side Effects Scale
Acceptability - side effects
Time frame: End of intervention phase (end of week 3)
Itemized treatment acceptability questionnaire
Acceptability - barriers and facilitators of attending appointments
Time frame: End of intervention phase (end of week 3)
Pregnancy Complications Itemized Questionnaire
Time frame: End of week 1
Pregnancy Complications Itemized Questionnaire
Time frame: End of week 2
Pregnancy Complications Itemized Questionnaire
Time frame: End of intervention phase (end of week 3)
Pregnancy Complications Itemized Questionnaire
Time frame: Every 4 weeks until delivery of baby (up to 26 weeks from initial randomization)
Pregnancy Complications Itemized Questionnaire
Time frame: 4 weeks postpartum
Rate of follow-up data collection
Time frame: 12 weeks postpartum
Completion of all 15 treatment sessions
Time frame: End of intervention phase (end of week 3)
Treatment allocation questionnaire
Time frame: End of week 1
Treatment allocation questionnaire
Time frame: End of intervention phase (end of week 3)
Montgomery Asberg Depression Rating Scale
Efficacy - Depression Symptom Measurement
Time frame: End of week 2
Edinburgh Postnatal Depression Scale
Efficacy - Depression Symptom Measurement
Time frame: End of Week 2
Montgomery Asberg Depression Rating Scale
Efficacy - Depression Symptom Measurement
Time frame: End of intervention phase (End of week 3)
Montgomery Asberg Depression Rating Scale
Efficacy - Depression Symptom Measurement
Time frame: Every 4 weeks until delivery (i.e. up to 26 weeks from initial randomization)
Montgomery Asberg Depression Rating Scale
Efficacy - Depression Symptom Measurement
Time frame: 4 weeks postpartum
Montgomery Asberg Depression Rating Scale
Efficacy - Depression Symptom Measurement
Time frame: 12 weeks postpartum
Edinburgh Postnatal Depression Scale
Efficacy - Depression Symptom Measurement
Time frame: End of intervention phase (Week 3)
Edinburgh Postnatal Depression Scale
Efficacy - Depression Symptom Measurement
Time frame: Every 4 weeks until delivery (i.e. up to 26 weeks from initial randomization)
Edinburgh Postnatal Depression Scale
Efficacy - Depression Symptom Measurement
Time frame: 4 weeks postpartum
Edinburgh Postnatal Depression Scale
Efficacy - Depression Symptom Measurement
Time frame: 12 weeks postpartum
Pregnancy Experience Scale
Efficacy - Secondary Symptom Measurement
Time frame: End of Week 2
Pregnancy Experience Scale
Efficacy - Secondary Symptom Measurement
Time frame: End of intervention phase (Week 3)
Pregnancy Experience Scale
Efficacy - Secondary Symptom Measurement
Time frame: Every 4 weeks until delivery (i.e. up to 26 weeks from initial randomization)
State-Trait Anxiety Inventory
Efficacy - Secondary Symptom Measurement
Time frame: End of week 2
State-Trait Anxiety Inventory
Efficacy - Secondary Symptom Measurement
Time frame: End of intervention phase (end of week 3)
State-Trait Anxiety Inventory
Efficacy - Secondary Symptom Measurement
Time frame: Every 4 weeks until delivery (i.e. up to 26 weeks from initial randomization)
State-Trait Anxiety Inventory
Efficacy - Secondary Symptom Measurement
Time frame: 4 weeks postpartum
State-Trait Anxiety Inventory
Efficacy - Secondary Symptom Measurement
Time frame: 12 weeks postpartum
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Women's College Hospital